Literature DB >> 23826732

High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.

Phoenix A Ho1, Todd A Alonzo, Robert B Gerbing, Jessica A Pollard, Betsy Hirsch, Susana C Raimondi, Todd Cooper, Alan S Gamis, Soheil Meshinchi.   

Abstract

Ectopic viral integration site-1 (EVI1) is highly expressed in certain cytogenetic subsets of adult acute myeloid leukaemia (AML), and has been associated with inferior survival. We sought to examine the clinical and biological associations of EVI1(high) , defined as expression in excess of normal controls, in paediatric AML. EVI1 mRNA expression was measured via quantitative real-time polymerase chain reaction in diagnostic specimens obtained from 206 patients. Expression levels were correlated with clinical features and outcome. EVI1(high) was present in 58/206 (28%) patients. MLL rearrangements occurred in 40% of EVI1(high) patients as opposed to 12% of the EVI1(low/absent) patients (P < 0·001). No abnormalities of 3q26 were found in EVI1(high) patients by conventional cytogenetic analysis, nor were cryptic 3q26 abnormalities detected in a subset of patients screened by next-generation sequencing. French-American-British class M7 was enriched in the EVI1(high) group, accounting for 24% of these patients. EVI1(high) patients had significantly lower 5-year overall survival from study entry (51% vs. 68%, P = 0·015). However, in multivariate analysis including other established prognostic markers, EVI1 expression did not retain independent prognostic significance. EVI1 expression is currently being studied in a larger cohort of patients enrolled on subsequent Children's Oncology Group trials, to determine if EVI1(high) has prognostic value in MLL-rearranged or intermediate-risk subsets.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  EVI1; MLL; acute myeloid leukaemia; paediatric cancer

Mesh:

Substances:

Year:  2013        PMID: 23826732      PMCID: PMC3754879          DOI: 10.1111/bjh.12444

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  29 in total

1.  WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group.

Authors:  Phoenix A Ho; Julia Kuhn; Robert B Gerbing; Jessica A Pollard; Rong Zeng; Kristen L Miller; Nyla A Heerema; Susana C Raimondi; Betsy A Hirsch; Janet L Franklin; Beverly Lange; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  Analyzing real-time PCR data by the comparative C(T) method.

Authors:  Thomas D Schmittgen; Kenneth J Livak
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

3.  EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.

Authors:  B V Balgobind; S Lugthart; I H Hollink; S T J C M Arentsen-Peters; E R van Wering; S S N de Graaf; D Reinhardt; U Creutzig; G J L Kaspers; E S J M de Bont; J Stary; J Trka; M Zimmermann; H B Beverloo; R Pieters; R Delwel; C M Zwaan; M M van den Heuvel-Eibrink
Journal:  Leukemia       Date:  2010-04-01       Impact factor: 11.528

4.  Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.

Authors:  Christine J Harrison; Robert K Hills; Anthony V Moorman; David J Grimwade; Ian Hann; David K H Webb; Keith Wheatley; Siebold S N de Graaf; Eva van den Berg; Alan K Burnett; Brenda E S Gibson
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

5.  High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.

Authors:  Stefan Gröschel; Sanne Lugthart; Richard F Schlenk; Peter J M Valk; Karina Eiwen; Chantal Goudswaard; Wim J L van Putten; Sabine Kayser; Leo F Verdonck; Michael Lübbert; Gert-Jan Ossenkoppele; Ulrich Germing; Ingo Schmidt-Wolf; Brigitte Schlegelberger; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Bob Löwenberg; Konstanze Döhner; Ruud Delwel
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

6.  CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression.

Authors:  Y Saito; S Nakahata; N Yamakawa; K Kaneda; E Ichihara; A Suekane; K Morishita
Journal:  Leukemia       Date:  2011-03-11       Impact factor: 11.528

7.  EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression.

Authors:  Francesca Cattaneo; Giuseppina Nucifora
Journal:  J Cell Biochem       Date:  2008-10-01       Impact factor: 4.429

8.  Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.

Authors:  Brian V Balgobind; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Rob Pieters; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Blood       Date:  2009-06-15       Impact factor: 22.113

9.  deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data.

Authors:  Andrew McPherson; Fereydoun Hormozdiari; Abdalnasser Zayed; Ryan Giuliany; Gavin Ha; Mark G F Sun; Malachi Griffith; Alireza Heravi Moussavi; Janine Senz; Nataliya Melnyk; Marina Pacheco; Marco A Marra; Martin Hirst; Torsten O Nielsen; S Cenk Sahinalp; David Huntsman; Sohrab P Shah
Journal:  PLoS Comput Biol       Date:  2011-05-19       Impact factor: 4.475

10.  Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.

Authors:  Phoenix A Ho; Matthew A Kutny; Todd A Alonzo; Robert B Gerbing; Jason Joaquin; Susana C Raimondi; Alan S Gamis; Soheil Meshinchi
Journal:  Pediatr Blood Cancer       Date:  2011-04-18       Impact factor: 3.838

View more
  14 in total

1.  EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.

Authors:  Hidemasa Matsuo; Mio Kajihara; Daisuke Tomizawa; Tomoyuki Watanabe; Akiko Moriya Saito; Junichiro Fujimoto; Keizo Horibe; Kumi Kodama; Mayu Tokumasu; Hiroshi Itoh; Hideki Nakayama; Akitoshi Kinoshita; Takashi Taga; Akio Tawa; Tomohiko Taki; Norio Shiba; Kentaro Ohki; Yasuhide Hayashi; Yuka Yamashita; Akira Shimada; Shiro Tanaka; Souichi Adachi
Journal:  Haematologica       Date:  2014-07-11       Impact factor: 9.941

2.  Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR.

Authors:  X He; Q Wang; J Cen; H Qiu; A Sun; S Chen; D Wu
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

3.  Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.

Authors:  N Sandhöfer; K H Metzeler; M Rothenberg; T Herold; S Tiedt; V Groiß; M Carlet; G Walter; T Hinrichsen; O Wachter; M Grunert; S Schneider; M Subklewe; A Dufour; S Fröhling; H-G Klein; W Hiddemann; I Jeremias; K Spiekermann
Journal:  Leukemia       Date:  2014-10-17       Impact factor: 11.528

Review 4.  Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.

Authors:  C Michel Zwaan; Edward A Kolb; Dirk Reinhardt; Jonas Abrahamsson; Souichi Adachi; Richard Aplenc; Eveline S J M De Bont; Barbara De Moerloose; Michael Dworzak; Brenda E S Gibson; Henrik Hasle; Guy Leverger; Franco Locatelli; Christine Ragu; Raul C Ribeiro; Carmelo Rizzari; Jeffrey E Rubnitz; Owen P Smith; Lillian Sung; Daisuke Tomizawa; Marry M van den Heuvel-Eibrink; Ursula Creutzig; Gertjan J L Kaspers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

5.  Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report.

Authors:  Era L Pogosova-Agadjanyan; Anna Moseley; Megan Othus; Frederick R Appelbaum; Thomas R Chauncey; I-Ming L Chen; Harry P Erba; John E Godwin; Min Fang; Kenneth J Kopecky; Alan F List; Galina L Pogosov; Jerald P Radich; Cheryl L Willman; Brent L Wood; Soheil Meshinchi; Derek L Stirewalt
Journal:  Biopreserv Biobank       Date:  2017-11-27       Impact factor: 2.256

6.  EVI1 promotes tumor growth via transcriptional repression of MS4A3.

Authors:  Gerwin Heller; Anna Rommer; Katarina Steinleitner; Julia Etzler; Hubert Hackl; Petra Heffeter; Erwin Tomasich; Martin Filipits; Birgit Steinmetz; Thais Topakian; Simone Klingenbrunner; Barbara Ziegler; Andreas Spittler; Sabine Zöchbauer-Müller; Walter Berger; Rotraud Wieser
Journal:  J Hematol Oncol       Date:  2015-03-21       Impact factor: 17.388

7.  EVI1 expression in childhood acute lymphoblastic leukaemia is not restricted to MLL and BCR/ABL rearrangements and is influenced by age.

Authors:  A Stevens; D Hanson; C de Leonibus; A Whatmore; R Donn; D J White; J Liu; M M van den Heuvel-Eibrink; V Saha; P E Clayton; S Meyer
Journal:  Blood Cancer J       Date:  2014-01-24       Impact factor: 11.037

8.  Gene therapy for Wiskott-Aldrich Syndrome-Long-term reconstitution and clinical benefits, but increased risk for leukemogenesis.

Authors:  Christian Joerg Braun; Maximilian Witzel; Anna Paruzynski; Kaan Boztug; Christof von Kalle; Manfred Schmidt; Christoph Klein
Journal:  Rare Dis       Date:  2014-10-30

9.  The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.

Authors:  Birgit Steinmetz; Hubert Hackl; Eva Slabáková; Ilse Schwarzinger; Monika Smějová; Andreas Spittler; Itziar Arbesu; Medhat Shehata; Karel Souček; Rotraud Wieser
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.

Authors:  Peter Tan; Ing Soo Tiong; Shaun Fleming; Giovanna Pomilio; Nik Cummings; Mark Droogleever; Julie McManus; Anthony Schwarer; John Catalano; Sushrut Patil; Sharon Avery; Andrew Spencer; Andrew Wei
Journal:  Oncotarget       Date:  2016-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.